BioCentury
ARTICLE | Company News

Taiwan approves TaiGen's nemonoxacin

March 13, 2014 11:39 PM UTC

TaiGen Biopharmaceuticals Holdings Ltd. (GreTai:4157) said the Taiwan Food and Drug Administration (TFDA) approved an NDA for oral Taigexyn nemonoxacin to treat community-acquired bacterial pneumonia (CABP). The non-fluorinated quinolone antibiotic topoisomerase inhibitor is under review in China. The company has exclusive, worldwide rights to nemonoxacin from Warner Chilcott plc, now part of Actavis plc (NYSE:ACT).

In January, TaiGen completed its IPO on the GreTai Securities Market, which valued the company at NT$34.8 billion ($1.1 billion) -- the highest post-IPO valuation ever for a biotech in Taiwan, according to the company. TaiGen is notable because it is developing NCEs, which are fairly new in Taiwan's pharmaceutical sector (see BioCentury, Jan. 27). ...